The captopril prevention project (CAPPP) in hypertension - Baseline data and current status

Blood Pressure

Volumn 6, Issue 6, 1997, Pages 365-367

  Hansson, Lennart ^a   Hedner, Thomas ^b   Lindholm, Lars ^b   Niklason, Anders ^b   Luomanmäki, Kimmo ^b   Niskanen, Leo ^b   Lanke, Jan ^b   Dahlöf, Björn ^b   De Faire, Ulf ^b   Mörlin, Claes ^b   Karlberg, Bengt E ^b   Wester, P O ^b   Björck, Jan Erik ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b NONE

Author keywords

ACE gene polymorphism; Angiotensin converting enzyme inhibition; Captopril; Hypertension; Intervention trial

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FINLAND; GENETIC POLYMORPHISM; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWEDEN; TREATMENT OUTCOME;

EID: 6844226192     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.3109/08037059709062096     Document Type: Article

References (16)

1. The CAPPP Group. The Captopril Prevention Project: A prospective intervention trial of angiotensin converting enzyme inhibition in the treatment of hypertension. J Hypertension 1990;8:985-90.
2. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: over-view of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
3. Levy D. Left ventricular hypertrophy. Epidemiological insights from the Framingham Heart Study. Drugs 1988;35 (suppl 5): 1-5.
4. Levy D, Garrison RJ, Sagae DD Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.
5. Dahlöf B, Herlitz H, Aurell M, Hansson L. Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin- angiotensin-aldosterone system. Am J Hypertens 1992;5:900-11.
6. Dahlöf B, Hansson L. The influence of antihypertensive treatment on the structural arteriolar changes in essential hypertension: differential effects of enalapril and hydrochlorothiazide. J Intern Med 1993;234:271-9.
7. Schiffrin EL, Deng LY, Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after two years of treatment with an angiotensin I converting enzyme inhibitor. Comparison with effects of a beta-blocker. Am J Hypertens 1995;8:229-36.
8. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
9. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996;275:1507-13.
10. Jennings GL, Wong J. Reversibility of left ventricular hypertrophy and malfunction by antihypertensive treatment. In: Handbook of Hypertension, Vol 18, Assessment of Hypertensive Organ Damage. Eds: Hansson L, Birkenhäger W H. Elsevier, Rotterdam 1997;184-223.
11. Himmelmann A, Hansson L, Hansson B-G, Hedstrand H, Skogström K, Öhrvik J, Furängen A. ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension. Blood Pressure 1995;4:85-90.
12. Himmelmann A, Hansson L, Hansson B-G, Hedstrand H, Skogström K, Öhrvik J, Furängen A. Long-term renal preservation in essential hypertension. Angiotensin converting enzyme inhibition is superior to beta-blockade. Am J Hypertens 1996;9:850-3.
13. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
14. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868-73.
15. Hansson L, Hedner T, Dahlöf B. Prospective Randomized Open Blinded End-point (PROBE) Study: A novel design for intervention trials. Blood Pressure 1992;1:113-9.
16. The West of Scotland Coronary Prevention Study Group. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J 1997 (submitted).